Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
MENLO PARK, Calif., Nov. 07, 2016 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:
- Stifel 2016 Healthcare Conference in New York at 9:30 a.m. ET on Tuesday, November 15, 2016.
- Piper Jaffray 28th Annual Healthcare Conference in New York at 12:30 p.m. ET on Wednesday, November 30, 2016.
A live audio webcast of each presentation will be available through the Homepage and Investor Relations section of Geron’s website under Events. Following the live presentations, the webcasts will be archived and available for replay for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
